Influence of repeat intrathecal triamcinolone acetonid application on CSF biomarkers in multiple sclerosis patients
Not Applicable
- Conditions
- G35.9
- Registration Number
- DRKS00005671
- Lead Sponsor
- niversitätsmedizin Rostock
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
Patients diagnosed with multiple scleroses, who are undergoing an antispastic symptomatic treatment with the intrathecally applicated corticosteroid triamcinolone acetonide. All patients had to be in a clinically stable condition at the beginning of the trial.
Exclusion Criteria
Clinically unstable condition. Abandonment of the triamcinolone acetonide treatment.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome is the investigation of the surrogates NfH, Tau-Protein, Protein S-100B in the cerebrospinal fluid of multiple sclerosis patients. The surrogates are measured in the cerebrospinal fluid according to the specific ELISA-methods. The cerebrospinal fluid is acquired within a cyclic antispastic therapy with triamcinolone acetnide.
- Secondary Outcome Measures
Name Time Method Secondary outcome of this trial are the results of clinical parameters: Expanded Disability Status Scale, Ashworthscale, Walking distance, timed 25-Foot Walk, bladder function, qualitiy of life. The parameters of every patient are measured within the hospitalization during the triamcinolone therapy by physicians and physiotherapists of each clinic.